Characterizing Baclofen Withdrawal: A National Survey of Physician Experience

Natalie S. Schmitz; Linda E. Krach; Lisa D. Coles; John Schrogie; James C. Cloyd; Robert L. Kriel

doi:10.1016/j.pediatrneurol.2021.06.007

Characterizing Baclofen Withdrawal: A National Survey of Physician Experience

Natalie S. Schmitz, Linda E. Krach, Lisa D. Coles, John Schrogie, James C. Cloyd, Robert L. Kriel

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Objective: We studied physicians’ opinions and experiences concerning clinical concerns, perceived severity, occurrence, and management of baclofen withdrawal due to abrupt discontinuation. Methods: A nationwide 26-question electronic survey was distributed via e-mail to physicians (N = 952) representing varying specialties who manage spasticity with baclofen. A total of 110 physicians provided responses to the survey (response rate = 11.6%). Results were evaluated using descriptive statistics. Results: Withdrawal from both oral and intrathecal (IT) baclofen was recognized as a significant concern and was observed by most respondents. However, approximately 75% and 35% of respondents or their clinic sites lack established management protocols for managing anticipated interruption of oral or IT baclofen, respectively. Conclusions: These findings highlight the need for further research on and the development of guidelines for the prevention and treatment of baclofen withdrawal. The results of this survey, along with a systematic literature review and multidisciplinary stakeholder input, may be helpful in establishing guidelines for the treatment and prevention of baclofen withdrawal.

Original language	English (US)
Pages (from-to)	106-109
Number of pages	4
Journal	Pediatric Neurology
Volume	122
DOIs	https://doi.org/10.1016/j.pediatrneurol.2021.06.007
State	Published - Sep 1 2021

Bibliographical note

Funding Information:
The authors gratefully acknowledge the contribution of Medtronic, Inc, who identified participants and distributed our survey. I am grateful for the mentoring, counseling, and friendship of Dr Kenneth (Ken) Swaiman, who encouraged me to pursue a career in academic medicine. Ken strongly supported my academic promotions. He also advised and helped with the review, editing, submission, and publication of my manuscripts. Robert (Bob) L. Kriel, M.D. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. There was no funding for this study.

Publisher Copyright:
© 2021 Elsevier Inc.

Keywords

Baclofen
Baclofen administration & dosage
Baclofen adverse effects
Muscle relaxants
Muscle spasticity
Muscle spasticity/drug therapy
Substance withdrawal syndrome/therapy
Survey

PubMed: MeSH publication types

Journal Article

Publisher link

10.1016/j.pediatrneurol.2021.06.007

Find It

Find It at U of M Libraries

Cite this

@article{d2b0d1003ab0489d8281e5c93b7077a1,

title = "Characterizing Baclofen Withdrawal: A National Survey of Physician Experience",

abstract = "Objective: We studied physicians{\textquoteright} opinions and experiences concerning clinical concerns, perceived severity, occurrence, and management of baclofen withdrawal due to abrupt discontinuation. Methods: A nationwide 26-question electronic survey was distributed via e-mail to physicians (N = 952) representing varying specialties who manage spasticity with baclofen. A total of 110 physicians provided responses to the survey (response rate = 11.6%). Results were evaluated using descriptive statistics. Results: Withdrawal from both oral and intrathecal (IT) baclofen was recognized as a significant concern and was observed by most respondents. However, approximately 75% and 35% of respondents or their clinic sites lack established management protocols for managing anticipated interruption of oral or IT baclofen, respectively. Conclusions: These findings highlight the need for further research on and the development of guidelines for the prevention and treatment of baclofen withdrawal. The results of this survey, along with a systematic literature review and multidisciplinary stakeholder input, may be helpful in establishing guidelines for the treatment and prevention of baclofen withdrawal.",

keywords = "Baclofen, Baclofen administration & dosage, Baclofen adverse effects, Muscle relaxants, Muscle spasticity, Muscle spasticity/drug therapy, Substance withdrawal syndrome/therapy, Survey",

author = "Schmitz, {Natalie S.} and Krach, {Linda E.} and Coles, {Lisa D.} and John Schrogie and Cloyd, {James C.} and Kriel, {Robert L.}",

note = "Funding Information: The authors gratefully acknowledge the contribution of Medtronic, Inc, who identified participants and distributed our survey. I am grateful for the mentoring, counseling, and friendship of Dr Kenneth (Ken) Swaiman, who encouraged me to pursue a career in academic medicine. Ken strongly supported my academic promotions. He also advised and helped with the review, editing, submission, and publication of my manuscripts. Robert (Bob) L. Kriel, M.D. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. There was no funding for this study. Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = sep,

day = "1",

doi = "10.1016/j.pediatrneurol.2021.06.007",

language = "English (US)",

volume = "122",

pages = "106--109",

journal = "Pediatric Neurology",

issn = "0887-8994",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Characterizing Baclofen Withdrawal

T2 - A National Survey of Physician Experience

AU - Schmitz, Natalie S.

AU - Krach, Linda E.

AU - Coles, Lisa D.

AU - Schrogie, John

AU - Cloyd, James C.

AU - Kriel, Robert L.

N1 - Funding Information: The authors gratefully acknowledge the contribution of Medtronic, Inc, who identified participants and distributed our survey. I am grateful for the mentoring, counseling, and friendship of Dr Kenneth (Ken) Swaiman, who encouraged me to pursue a career in academic medicine. Ken strongly supported my academic promotions. He also advised and helped with the review, editing, submission, and publication of my manuscripts. Robert (Bob) L. Kriel, M.D. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. There was no funding for this study. Publisher Copyright: © 2021 Elsevier Inc.

PY - 2021/9/1

Y1 - 2021/9/1

N2 - Objective: We studied physicians’ opinions and experiences concerning clinical concerns, perceived severity, occurrence, and management of baclofen withdrawal due to abrupt discontinuation. Methods: A nationwide 26-question electronic survey was distributed via e-mail to physicians (N = 952) representing varying specialties who manage spasticity with baclofen. A total of 110 physicians provided responses to the survey (response rate = 11.6%). Results were evaluated using descriptive statistics. Results: Withdrawal from both oral and intrathecal (IT) baclofen was recognized as a significant concern and was observed by most respondents. However, approximately 75% and 35% of respondents or their clinic sites lack established management protocols for managing anticipated interruption of oral or IT baclofen, respectively. Conclusions: These findings highlight the need for further research on and the development of guidelines for the prevention and treatment of baclofen withdrawal. The results of this survey, along with a systematic literature review and multidisciplinary stakeholder input, may be helpful in establishing guidelines for the treatment and prevention of baclofen withdrawal.

AB - Objective: We studied physicians’ opinions and experiences concerning clinical concerns, perceived severity, occurrence, and management of baclofen withdrawal due to abrupt discontinuation. Methods: A nationwide 26-question electronic survey was distributed via e-mail to physicians (N = 952) representing varying specialties who manage spasticity with baclofen. A total of 110 physicians provided responses to the survey (response rate = 11.6%). Results were evaluated using descriptive statistics. Results: Withdrawal from both oral and intrathecal (IT) baclofen was recognized as a significant concern and was observed by most respondents. However, approximately 75% and 35% of respondents or their clinic sites lack established management protocols for managing anticipated interruption of oral or IT baclofen, respectively. Conclusions: These findings highlight the need for further research on and the development of guidelines for the prevention and treatment of baclofen withdrawal. The results of this survey, along with a systematic literature review and multidisciplinary stakeholder input, may be helpful in establishing guidelines for the treatment and prevention of baclofen withdrawal.

KW - Baclofen

KW - Baclofen administration & dosage

KW - Baclofen adverse effects

KW - Muscle relaxants

KW - Muscle spasticity

KW - Muscle spasticity/drug therapy

KW - Substance withdrawal syndrome/therapy

KW - Survey

UR - http://www.scopus.com/inward/record.url?scp=85111244660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85111244660&partnerID=8YFLogxK

U2 - 10.1016/j.pediatrneurol.2021.06.007

DO - 10.1016/j.pediatrneurol.2021.06.007

M3 - Article

C2 - 34330615

AN - SCOPUS:85111244660

SN - 0887-8994

VL - 122

SP - 106

EP - 109

JO - Pediatric Neurology

JF - Pediatric Neurology

ER -

Characterizing Baclofen Withdrawal: A National Survey of Physician Experience

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

Publisher link

Find It

Other files and links

Fingerprint

Cite this